[14]Amiri-Kordestani L, Blumenthal GM, Xu QC, et al. FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014;20(17):4436-4441. [15]Krop IE, Kim SB, González-Martín A, et al. Trastuzumab emtansine versus...
If confirmed, this new paradigm would potentially expand the population deriving benefit from HER2-targeted treatments to up to 70% of all advanced BC patients, leading to a revolution in current treatment algorithms, and possibly to a redefinition of HER2 classification.Paolo Tarantino...
[5]、Giordano SH.Breast Cancer in Men.N Engl J Med.2018;378(24):2311-2320.doi:10.1056/NEJMra1707939 [6]、FDA.Male Breast Cancer:Developing Drugs for Treatment Guidance for Industry.Published online August,2020.Available at:https://www.fda.gov/media/130061/download [7]、中国临床肿瘤学会指南...
[47]Nagaraja Shastri P, Zhu J, Skidmore L, et al. Nonclinical Development of Next-generation Site-specific HER2-targeting Antibody-drug Conjugate (ARX788) for Breast Cancer Treatment. Mol Cancer Ther. 2020;19(9):1822-1832. [48]Hu X, Zhang J, Ji D, et al. a phase 1 study of ARX78...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal antibody trastuzumab — almost 25 years ago....
Herceptin is an intravenous drug that is part of a chemotherapy regimen that is used to prevent recurrence ofbreast cancer, and for the treatment breastcancerthat has spread beyond the breast (metastasized). It belongs to a class ofdrugscalled monoclonal antibodies. Other monoclonal antibodies includ...
“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed therapi...
What is your opinion on the use of combination therapies in HER2-positive breast cancer treatment? In general, patients with HER2-positive breast cancer always receive combination therapy. In the early-stage setting, we are adding chemotherapy to anti-HER2 drugs and antibodies as previously discussed...
[21]. Marmé F, et al. Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk aft...
HERCEPTIN HYLECTA (trastuzumab and hyaluronidase-oysk) is approved for the treatment of adults with early-stage breast cancer that isHumanEpidermal growth factorReceptor2-positive (HER2+) and has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it ...